These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 34155670)

  • 1. Mirtazapine use may increase the risk of hypothyroxinaemia in patients affected by major depressive disorder.
    Zhao Y; Wang N; Wen SW; Li M; Yuan Y; Retnakaran R; Hao W; Zhang R; Zhai D
    Br J Clin Pharmacol; 2022 Jan; 88(1):214-225. PubMed ID: 34155670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxcarbazepine was associated with risks of newly developed hypothyroxinaemia and impaired central set point of thyroid homeostasis in schizophrenia patients.
    Zhai D; Chen J; Guo B; Retnakaran R; Gao S; Zhang X; Hao W; Zhang R; Zhao Y; Wen SW
    Br J Clin Pharmacol; 2022 May; 88(5):2297-2305. PubMed ID: 34855997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired central set point of thyroid homeostasis during quetiapine treatment in the acute phase of schizophrenia.
    Zhao Y; Guan Q; Shi J; Sun J; Wang Q; Yang J; Retnakaran R; Han J; Zhang X; Hao W; Huang X; Zhang R; Zhai D; Wen SW
    Schizophr Res; 2022 Mar; 241():244-250. PubMed ID: 35180663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher central set point of thyroid homeostasis in drug-naïve patients affected by first episode schizophrenia.
    Zhai D; Bing J; Shan X; Luo H; Wen W; Gao S; Niu K; Cui T; Li H; Retnakaran R; Hao W; Zhang R; Zhao Y; Wen SW
    Schizophr Res; 2022 Dec; 250():62-66. PubMed ID: 36368279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postnatal thyroid hormones for preterm infants with transient hypothyroxinaemia.
    Osborn DA; Hunt RW
    Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD005945. PubMed ID: 17253568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial.
    Kato T; Furukawa TA; Mantani A; Kurata K; Kubouchi H; Hirota S; Sato H; Sugishita K; Chino B; Itoh K; Ikeda Y; Shinagawa Y; Kondo M; Okamoto Y; Fujita H; Suga M; Yasumoto S; Tsujino N; Inoue T; Fujise N; Akechi T; Yamada M; Shimodera S; Watanabe N; Inagaki M; Miki K; Ogawa Y; Takeshima N; Hayasaka Y; Tajika A; Shinohara K; Yonemoto N; Tanaka S; Zhou Q; Guyatt GH;
    BMC Med; 2018 Jul; 16(1):103. PubMed ID: 29991347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial.
    Cornelius JR; Chung T; Douaihy AB; Kirisci L; Glance J; Kmiec J; FitzGerald D; Wesesky MA; Salloum I
    Psychiatry Res; 2016 Aug; 242():326-330. PubMed ID: 27327217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal thyroid hormone insufficiency during pregnancy and risk of neurodevelopmental disorders in offspring: A systematic review and meta-analysis.
    Thompson W; Russell G; Baragwanath G; Matthews J; Vaidya B; Thompson-Coon J
    Clin Endocrinol (Oxf); 2018 Apr; 88(4):575-584. PubMed ID: 29325223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The measurement, definition, aetiology and clinical consequences of neonatal transient hypothyroxinaemia.
    Williams F; Hume R
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):7-22. PubMed ID: 20930033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of mirtazapine on thyroid hormones in adult patients with major depression.
    Gambi F; De Berardis D; Sepede G; Campanella D; Galliani N; Carano A; La Rovere L; Salini G; Penna L; Cicconetti A; Spinella S; Quartesan R; Salerno RM; Ferro FM
    Int J Immunopathol Pharmacol; 2005; 18(4):737-44. PubMed ID: 16388723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First trimester isolated maternal hypothyroxinaemia: adverse maternal metabolic profile and impact on the obstetrical outcome.
    Furnica RM; Gruson D; Lazarus JH; Maiter D; Bernard P; Daumerie C
    Clin Endocrinol (Oxf); 2017 Apr; 86(4):576-583. PubMed ID: 28039875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis.
    Watanabe N; Omori IM; Nakagawa A; Cipriani A; Barbui C; McGuire H; Churchill R; Furukawa TA;
    CNS Drugs; 2010 Jan; 24(1):35-53. PubMed ID: 20030418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the adrenergic alpha 2a receptor--1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder.
    Lee HY; Kang RH; Paik JW; Jeong YJ; Chang HS; Han SW; Lee MS
    Brain Res; 2009 Mar; 1262():1-6. PubMed ID: 19401164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study.
    Reis M; Prochazka J; Sitsen A; Ahlner J; Bengtsson F
    Ther Drug Monit; 2005 Aug; 27(4):469-77. PubMed ID: 16044104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine.
    Cankurtaran ES; Ozalp E; Soygur H; Akbiyik DI; Turhan L; Alkis N
    Support Care Cancer; 2008 Nov; 16(11):1291-8. PubMed ID: 18299900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients.
    Shen J; Moller HJ; Wang X; Chung SA; Shapiro GK; Li X; Shapiro CM
    J Clin Psychiatry; 2009 Mar; 70(3):370-7. PubMed ID: 19192466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder.
    Kasper S; Montgomery SA; Möller HJ; van Oers HJ; Jan Schutte A; Vrijland P; van der Meulen EA
    World J Biol Psychiatry; 2010 Feb; 11(1):36-44. PubMed ID: 20146649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of transthyretin and thyroxine-binding globulin in major depressive disorder: multiple reaction monitoring-based proteomic analysis.
    Woo HI; Park J; Lim SW; Kim DK; Lee SY
    J Transl Med; 2021 Jan; 19(1):34. PubMed ID: 33451315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of isolated maternal hypothyroxinaemia on the incidence of large-for-gestational-age infants: the Ma'anshan Birth Cohort study.
    Zhu YD; Han Y; Huang K; Zhu BB; Yan SQ; Ge X; Zhou SS; Xu YY; Ren LI; Sheng J; Pan WJ; Hao JH; Zhu P; Tao FB
    BJOG; 2018 Aug; 125(9):1118-1125. PubMed ID: 29266657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.